Mizuho Reiterates Buy on Arcutis Biotherapeutics, Maintains $57 Price Target
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Uy Ear has reiterated a 'Buy' rating on Arcutis Biotherapeutics (NASDAQ:ARQT) and maintained a price target of $57.
September 25, 2023 | 3:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst has reiterated a 'Buy' rating on Arcutis Biotherapeutics and maintained a price target of $57.
The reiteration of a 'Buy' rating by a Mizuho analyst and the maintenance of a $57 price target indicates a positive outlook for Arcutis Biotherapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock's short-term price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100